Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Japan Becoming Less Priority Market as Policy Changes Mar Predictability: MSD Exec
July 19, 2022
- Edirol Hits Chinese Market: Chugai
July 19, 2022
- Shionogi COVID Pill Shows Antiviral Activity Against BA.5
July 15, 2022
- Ultragenyx Takes Over Mepsevii Marketing Authorization in Japan
July 15, 2022
- Shingrix Shows Cost-Effectiveness in Japanese Older Adults: GSK Analysis
July 15, 2022
- Pfizer Japan Files COVID-19 Vaccine for Ages 6 Months to 4 Years
July 15, 2022
- Mochida to Discontinue Filgrastim Biosimilars Despite 50% Share
July 14, 2022
- Financially Weak Companies Will Go Under If Annual Price Cuts Continue: Sawai Chair
July 14, 2022
- BMS Japan on Track to Achieve Goals in Mid-Term Biz Plan: Chief
July 14, 2022
- Shionogi’s Four-Day Workweek Not So Popular Yet, but Side Job Plan Gaining Traction
July 13, 2022
- Healios to Provide iPSC Line to RxCell; License Talks with StemAxon Gets Underway
July 13, 2022
- Ex-Novartis Exec Jugo Tsumura Takes Reins at Ferring Japan
July 12, 2022
- Takeda Showcases Manufacturing Line for Cell Therapy Alofisel
July 11, 2022
- Organon Curbs Shipment of Fertility Med Ganirest in Japan
July 11, 2022
- As LOEs Loom, Can Mochida Roll Out Authorized Generics for Lexapro and Lialda?
July 8, 2022
- Shipment Restrictions Continue for Vyndaqel, Vynmac: Pfizer Japan
July 8, 2022
- Japan Ethical Drug Sales Surge 6.2% in May: Crecon
July 8, 2022
- Lilly Japan, Mitsubishi Tanabe Link Up to Copromote Diabetes Med Tirzepatide
July 8, 2022
- Meiji Pharma/KM Biologics Eager to Acquire mRNA Vaccine, Mull Collabs with Upstarts and Academia
July 7, 2022
- KD-414 Presumed to Have Superior Efficacy over Vaxzevria: KM Bio President
July 7, 2022
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…